'Low-Hanging Fruit' Of Industry Comms Policy Addressed By Recent FDA Documents

22 Mar 2017
Analysis

Elizabeth Orr @elizabethjorr elizabeth.orr@informa.com

Executive Summary

Draft guidance documents issues by US FDA in January did not tackle the toughest off-label speech debates, but they did provide some useful information to guide company communications, experts said on a recent FDLI webinar.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Regulation Advertising, Marketing & Sales Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT104621

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT104621

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

'Low-Hanging Fruit' Of Industry Comms Policy Addressed By Recent FDA Documents

Analysis

Executive Summary

Related Content

FDA Cracks Open Door For More Manufacturer Communications

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert